Boston Scientific Corporation $BSX Stock: Frank Rimerman Advisors LLC Boosts Stake

Frank Rimerman Advisors LLC boosted its stake in Boston Scientific Corporation (NYSE:BSX) by 112.4% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 37,407 shares of the medical equipment provider’s stock after buying an additional 19,797 shares during the quarter. Frank Rimerman Advisors LLC’s holdings in Boston Scientific were worth $1,800,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in BSX. Kelleher Financial Advisors acquired a new position in Boston Scientific in the second quarter valued at about $25,000. Clal Insurance Enterprises Holdings Ltd bought a new stake in Boston Scientific during the 1st quarter worth about $28,000. Nvwm LLC grew its stake in shares of Boston Scientific by 526.2% during the third quarter. Nvwm LLC now owns 645 shares of the medical equipment provider’s stock valued at $28,000 after purchasing an additional 542 shares during the last quarter. Rakuten Securities Inc. acquired a new position in Boston Scientific during the 2nd quarter worth $30,000. Finally, Cassaday & Co Wealth Management LLC bought a new position in Boston Scientific in the 1st quarter valued at $32,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific Trading Up 0.5%

BSX opened at $44.34 on Friday. The firm has a 50 day simple moving average of $46.06 and a 200 day simple moving average of $49.76. Boston Scientific Corporation has a fifty-two week low of $41.38 and a fifty-two week high of $105.65. The company has a market cap of $64.26 billion, a price-to-earnings ratio of 17.95, a price-to-earnings-growth ratio of 1.07 and a beta of 0.58. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 0.74.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.83 by $0.03. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The firm had revenue of $5.44 billion for the quarter, compared to analysts’ expectations of $5.38 billion. During the same period last year, the firm earned $0.75 earnings per share. The business’s revenue for the quarter was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, sell-side analysts anticipate that Boston Scientific Corporation will post 3.24 earnings per share for the current year.

Insider Buying and Selling at Boston Scientific

In related news, Director David C. Habiger purchased 2,100 shares of Boston Scientific stock in a transaction dated Wednesday, August 5th. The shares were acquired at an average cost of $47.59 per share, for a total transaction of $99,939.00. Following the transaction, the director directly owned 17,160 shares of the company’s stock, valued at approximately $816,644.40. This trade represents a 13.94% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Edward J. Ludwig acquired 5,000 shares of the firm’s stock in a transaction that occurred on Friday, July 31st. The shares were bought at an average cost of $45.48 per share, with a total value of $227,400.00. Following the completion of the purchase, the director owned 30,359 shares of the company’s stock, valued at $1,380,727.32. This trade represents a 19.72% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last 90 days, insiders acquired 194,522 shares of company stock worth $9,385,210. Insiders own 0.34% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently commented on BSX. The Goldman Sachs Group lowered their target price on Boston Scientific from $71.00 to $57.00 and set a “buy” rating for the company in a research note on Tuesday, July 14th. Canaccord Genuity Group dropped their target price on Boston Scientific from $70.00 to $66.00 and set a “buy” rating for the company in a research report on Thursday, July 30th. Wall Street Zen lowered Boston Scientific from a “buy” rating to a “hold” rating in a research note on Sunday, August 2nd. Royal Bank Of Canada decreased their price target on Boston Scientific from $85.00 to $70.00 and set an “outperform” rating on the stock in a report on Thursday, July 30th. Finally, Mizuho set a $55.00 price target on Boston Scientific in a report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, twenty-five have assigned a Buy rating, three have issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $68.23.

Boston Scientific Profile

Boston Scientific Corporation is a medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of complex medical conditions. Founded in 1979 and headquartered in Marlborough, Massachusetts, the company serves healthcare providers and patients worldwide.

Its products support minimally invasive procedures in areas including interventional cardiology, peripheral interventions, electrophysiology, endoscopy, urology and neuromodulation.